Crestline Management’s Immunome IMNM Stock Holding History

Crestline Management’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-24,744	Closed	-$263K	–	310
2024 Q4	$263K	Buy	+24,744	New	+$299K	0.01%	637

Other funds holding IMNM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Crestline Management's IMNM Position: Q1 2025 in Review

Crestline Management sold out of Immunome (IMNM) in Q1 2025, closing a stake of 24,744 shares — an estimated $263K sold.

Crestline Management first reported a position in IMNM in Q4 2024 and held it in 1 quarter. The position peaked at $263K in Q4 2024. 142 funds tracked by Wall St. Rank hold IMNM as of Q1 2025.

Crestline Management reported no remaining Immunome position as of Q1 2025 after selling out during the quarter.
Crestline Management sold 24,744 Immunome shares in Q1 2025, an estimated $263K.
Crestline Management first reported a position in Immunome in Q4 2024 and held it in 1 quarter.
Crestline Management's Immunome position peaked at $263K in Q4 2024.
142 funds tracked by Wall St. Rank held Immunome as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.